LH-RH ANALOG TREATMENT IN ADENOCARCINOMA OF THE PANCREAS - A PHASE-II STUDY

被引：0

作者：

ALLEGRETTI, A

LIONETTO, R

SACCOMANNO, S

PAGANUZZI, M

ONETTO, M

MARTINOLI, C

ROLLANDI, G

MARUGO, M

FAZZUOLI, L

PUGLIESE, V

AZIONI, R

ARCURI, V

PERCIVALE, PL

BORGONOVO, G

BARTOLI, FG

机构：

[1] IST NAZL RIC CANC,SERV EPIDEMIOL CLIN & SPERIMENTAZ CONTROLLATE,GENOA,ITALY

[2] IST NAZL RIC CANC,SERV PATOL CLIN,GENOA,ITALY

[3] UNIV GENOA,IST RADIOL R,I-16126 GENOA,ITALY

[4] UNIV GENOA,IST ENDOCRINOL,I-16126 GENOA,ITALY

[5] UNIV GENOA,IST CLIN CHIRURG B,I-16126 GENOA,ITALY

[6] OSPEDALE S MARTINO,DIV CHIRURG GEN,GENOA,ITALY

[7] OSPEDALE S MARTINO,DIV CHIRURG TRAPIANTI,GENOA,ITALY

[8] UNIV GENOA,IST CLIN CHIRURG R,I-16126 GENOA,ITALY

来源：

ONCOLOGY | 1993年 / 50卷 / 02期

关键词：

PANCREATIC ADENOCARCINOMA; HORMONAL MANIPULATION; ANTIANDROGENS;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this phase II study, we treated 7 patients, all males, with stage III or IV pancreatic cancer with goserelin (an LH-RH analogue). Goserelin was administered at a dose of 3.6 mg every 4 weeks. The tumour response was assessed by measuring lesions with US- or CT-scan studies, according to WHO criteria. No response was observed. The median survival was 8 months in locally unresectable tumours and 4 months in advanced disease. The accrual was actually stopped at 7 cases because there were no responses in either of our series or in those published during our study. The authors conclude that the treatment with LH-RH analogue alone cannot be recommended for further studies.

引用

页码：77 / 80

页数：4

共 29 条

[1]

ANDRENSANDBERG A, 1982, DIGESTION, V25, P12

[2] ESTROGENS AND PANCREATIC-CANCER - SOME RECENT ASPECTS [J].